1260 related articles for article (PubMed ID: 24969297)
1. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
Merga Y; Campbell BJ; Rhodes JM
Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
[TBL] [Abstract][Full Text] [Related]
2. Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn's disease.
Keita AV; Salim SY; Jiang T; Yang PC; Franzén L; Söderkvist P; Magnusson KE; Söderholm JD
J Pathol; 2008 Jun; 215(2):135-44. PubMed ID: 18348161
[TBL] [Abstract][Full Text] [Related]
3. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
[TBL] [Abstract][Full Text] [Related]
4. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
5. Mucosal flora in Crohn's disease and ulcerative colitis - an overview.
Swidsinski A; Loening-Baucke V; Herber A
J Physiol Pharmacol; 2009 Dec; 60 Suppl 6():61-71. PubMed ID: 20224153
[TBL] [Abstract][Full Text] [Related]
6. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease.
Strugala V; Dettmar PW; Pearson JP
Int J Clin Pract; 2008 May; 62(5):762-9. PubMed ID: 18194279
[TBL] [Abstract][Full Text] [Related]
7. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
Stecher B
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
[TBL] [Abstract][Full Text] [Related]
8. Peyer's patches and M cells as potential sites of the inflammatory onset in Crohn's disease.
Gullberg E; Söderholm JD
Ann N Y Acad Sci; 2006 Aug; 1072():218-32. PubMed ID: 17057202
[TBL] [Abstract][Full Text] [Related]
9. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid.
Kabeerdoss J; Jayakanthan P; Pugazhendhi S; Ramakrishna BS
Indian J Med Res; 2015 Jul; 142(1):23-32. PubMed ID: 26261163
[TBL] [Abstract][Full Text] [Related]
10.
Loganes C; Valencic E; Pin A; Marini E; Martelossi S; Naviglio S; De Leo L; Not T; Monasta L; Tommasini A; Marcuzzi A
World J Gastroenterol; 2016 Nov; 22(44):9734-9743. PubMed ID: 27956797
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the intestinal mucosal block in ulcerative colitis and Crohn's disease--immunological and ultrastructural findings, and considerations of the pathogenesis.
Gebbers JO; Otto HF
Klin Padiatr; 1985; 197(4):341-8. PubMed ID: 4046492
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
Hering NA; Schulzke JD
Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
[TBL] [Abstract][Full Text] [Related]
13. Fungi and inflammatory bowel diseases: Alterations of composition and diversity.
Ott SJ; Kühbacher T; Musfeldt M; Rosenstiel P; Hellmig S; Rehman A; Drews O; Weichert W; Timmis KN; Schreiber S
Scand J Gastroenterol; 2008; 43(7):831-41. PubMed ID: 18584522
[TBL] [Abstract][Full Text] [Related]
14. Polarized production of T-helper cell type 1 cells in Peyer's patches in Crohn's disease.
Kudo T; Nagata S; Aoyagi Y; Suzuki R; Matsuda H; Ohtsuka Y; Shimizu T; Okumura K; Yamashiro Y
Digestion; 2004; 70(4):214-25. PubMed ID: 15627769
[TBL] [Abstract][Full Text] [Related]
15. Intestinal mucus barrier in normal and inflamed colon.
Corazziari ES
J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S54-5. PubMed ID: 19300126
[TBL] [Abstract][Full Text] [Related]
16. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
Sartor RB
Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the mucosa-associated bacterial composition in Crohn's disease: a pilot study.
Schäffler H; Kaschitzki A; Alberts C; Bodammer P; Bannert K; Köller T; Warnke P; Kreikemeyer B; Lamprecht G
Int J Colorectal Dis; 2016 May; 31(5):961-971. PubMed ID: 26951181
[TBL] [Abstract][Full Text] [Related]
18. Microbiota and mucosal defense in IBD: an update.
Stange EF; Schroeder BO
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):963-976. PubMed ID: 31603356
[No Abstract] [Full Text] [Related]
19. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.
Caradonna L; Amati L; Magrone T; Pellegrino NM; Jirillo E; Caccavo D
J Endotoxin Res; 2000; 6(3):205-14. PubMed ID: 11052175
[TBL] [Abstract][Full Text] [Related]
20. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.
Hansen R; Russell RK; Reiff C; Louis P; McIntosh F; Berry SH; Mukhopadhya I; Bisset WM; Barclay AR; Bishop J; Flynn DM; McGrogan P; Loganathan S; Mahdi G; Flint HJ; El-Omar EM; Hold GL
Am J Gastroenterol; 2012 Dec; 107(12):1913-22. PubMed ID: 23044767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
